12/4
07:18 am
ikt
Inhibikase Therapeutics (NASDAQ:IKT) was upgraded by analysts at Zacks Research to a "hold" rating.
Medium
Report
Inhibikase Therapeutics (NASDAQ:IKT) was upgraded by analysts at Zacks Research to a "hold" rating.
12/2
06:16 am
ikt
Inhibikase Therapeutics (NASDAQ:IKT) was upgraded by analysts at Lifesci Capital to a "strong-buy" rating.
Medium
Report
Inhibikase Therapeutics (NASDAQ:IKT) was upgraded by analysts at Lifesci Capital to a "strong-buy" rating.
11/20
10:12 pm
ikt
Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]
Medium
Report
Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]
11/20
09:54 pm
ikt
Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
Medium
Report
Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
11/20
06:04 pm
ikt
Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]
Medium
Report
Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]
11/20
04:12 pm
ikt
Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Medium
Report
Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
11/20
04:01 pm
ikt
Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension
Low
Report
Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension
11/14
05:41 pm
ikt
Inhibikase Therapeutics GAAP EPS of -$0.13 [Seeking Alpha]
Low
Report
Inhibikase Therapeutics GAAP EPS of -$0.13 [Seeking Alpha]
11/14
04:01 pm
ikt
Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity
Neutral
Report
Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity
9/20
01:09 am
ikt
Inhibikase Therapeutics (NASDAQ:IKT) was upgraded by analysts at
Wall Str
Low
Report
Inhibikase Therapeutics (NASDAQ:IKT) was upgraded by analysts at
Wall Str